ni Beth Camia
Hindi dapat gamitin panggamot sa COVID-19 ang Ivermectin, babala ngWorld Health Organization sa Pilipinas.
“The issue with Ivermectin is that based on that initial study and the currently available data it is not strong enough for us to advocate the use of Ivermectin for treatment or prevention of COVID,” ani Dr. Rabindra Abeyasinghe, WHO representative to the Philippines.
“We had a similar situation in the hydroxychloroquine a few months ago, if you remember, and then when WHO did the details in the solidarity trials, it was conclusively shown that hydroxychloroquine not of them had any efficacy in reducing the severity or in protecting COVID-19 infection,” lahad pa ni Abeyasinghe.
Lalaking nambuhos ng mainit na kape sa jowa, sugatan matapos tagain at gantihan
Sinabi rin nito na batay sa rekomendasyon ng European Medical Association at US FDA na hindi dapat gamiting pang-gamot sa COVID-19 ang nasabing gamot.
“What they are recommending is that we look at carefully planned controlled clinical trials to have a proof whether Ivermectin works that is the global evidence that we have not only from WHO but also from very stringent regulatory authority and medicines authority both in Europe and in North America,” giit pa ni Abeyasinghe.
Punto pa nito na maaaring makagawa ito ng hindi tiyak na pag-asa sa publiko kung patuloy itong gagamitin.
“What we are actually creating is a false confidence in people that if they take Ivermectin they are going to be protected and that could actually be harmful,” aniya pa.
Una nang tinutulan ng DoH ang paggamit nito bilang lunas sa COVID-19.
“A systematic review of 6 randomized control trials of good methodological quality shows that first the use of ivermectin for the treatment of COVID-19 does not reduce mortality risk. It is also not associated with a definite benefit in terms of other clinically important outcomes such as clinical improvement at day 6 to 10 clinical deterioration nor need for a mechanical ventilation,” paliwanag ni DOH spokesperson Usec. Rosette Singh-Vergeire.
Ito ay base sa pag-aaral ng UP-NIH ICE and Consensus Panel Representative of FDA-DOH, PMA, PCP, PAFP, POGS, PCEM, PSGIM, PCCP, PSPHP, at PSMID.
“Furthermore it does not significantly reduce the duration of hospitalization and the time to resolution of symptoms. The rate of hospital discharge at day 10 to 14 does not differ significantly between those given ivermectin and those who received standards of care or placebo,” dagdag ni Vergeire.
“Based on the current evidence from the randomized controlled trials, we do not recommend the use of ivermectin for the treatment of COVID-19 as it has not been proven to significantly reduce mortality or improve other clinical outcomes this recommendation will be updated as more evidence will be generated from our on-going trials,” saad pa nito.
Isinusulong sa kasalukuyan ang pagpapabilis ng FDA sa pag-apruba sa paggamit ng Ivermectin bilang lunas sa virus.
